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Background: GRK5 is implicated in several human pathologies, but relatively little is known about its structure and
function.
Results: High resolution crystal structures of human GRK5 with AMP-PNP and sangivamycin were determined.
Conclusion: GRK5 is found in a partially closed state with its kinase domain C-tail forming novel interactions with nucleotide
and the N-lobe.
Significance: The GRK5 structure provides important insight into its function.
G protein-coupled receptor kinases (GRKs) are members of
the protein kinase A, G, and C families (AGC) and play a central
role in mediating G protein-coupled receptor phosphorylation
and desensitization. Onemember of the family, GRK5, has been
implicated in several human pathologies, including heart fail-
ure, hypertension, cancer, diabetes, and Alzheimer disease. To
gain mechanistic insight into GRK5 function, we determined a
crystal structure of full-length human GRK5 at 1.8 Å resolu-
tion. GRK5 in complex with the ATP analog 5-adenylyl
,-imidodiphosphate or the nucleoside sangivamycin crystal-
lized as a monomer. The C-terminal tail (C-tail) of AGC kinase
domains is a highly conserved feature that is divided into three
segments as follows: the C-lobe tether, the active-site tether
(AST), and the N-lobe tether (NLT). This domain is fully
resolved in GRK5 and reveals novel interactions with the nucle-
otide and N-lobe. Similar to other AGC kinases, the GRK5 AST
is an integral part of thenucleotide-bindingpocket, a featurenot
observed in other GRKs. The AST also mediates contact
between the kinase N- and C-lobes facilitating closure of the
kinase domain. TheGRK5NLT is largely displaced from its pre-
viously observed position in other GRKs. Moreover, although
the autophosphorylation sites in the NLT are>20 Å away from
the catalytic cleft, they are capable of rapid cis-autophosphory-
lation suggesting high mobility of this region. In summary, we
provide a snapshot of GRK5 in a partially closed state, where
structural elements of the kinase domain C-tail are aligned to
form novel interactions to the nucleotide and N-lobe not previ-
ously observed in other GRKs.
The G protein-coupled receptor kinase (GRK)3 family dates
back to the discovery of rhodopsin kinase (GRK1) and now
includes seven members that fall into the following three sub-
families: GRK1 (GRK1 and -7), GRK2 (GRK2 and -3), and
GRK4 (GRK4–6) (1–3). GRKs are best known for their ability
to phosphorylate activated G protein-coupled receptors
(GPCRs) and promote arrestin binding, a process that drives
receptor desensitization and trafficking as well as arrestin-me-
diated signaling (1–3). GRKs also phosphorylate many other
proteins and can mediate kinase-independent regulation of
receptor and effector function (2). Although most GRKs are
localized in the cytoplasm or at the plasma membrane, GRK5
andGRK6 are also found in the nucleus withGRK5 localization
being regulated by Gq signaling (4, 5) and GRK6 localization
regulated by palmitoylation (6). These findings suggest many
novel ways whereby GRKsmaymediate their biological effects.
GRKs have been implicated inmany pathological conditions,
including cardiovascular disease, cancer, and various neurolog-
ical andmetabolic disorders (2, 3). This has been best studied in
cardiovascular diseasewhere increasedGRKexpression is asso-
ciated with congestive heart failure, hypertension, andmyocar-
dial ischemia. GRK2 appears to play a particularly important
role in this process and is overexpressed in human heart failure
and hypertension as well as in experimentally induced heart
failure models (7–9). GRK5 is also linked with cardiovascular
disease and contributes to cardiac hypertrophy (10) and hyper-
tension (11). Moreover, a Q41L polymorphism within the reg-
ulator ofGprotein signaling homology (RH) domain inGRK5 is
prevalent in African Americans and has an enhanced ability to
desensitize the 2-adrenergic receptor (2AR) (12) and protect
against the development of congestive heart failure (13). GRK5
has also been linked with type 2 diabetes (14), prostate tumor
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growth (15) andmetastasis (16), Parkinsondiseasewith demen-
tia (17), synuclein phosphorylation and aggregation in sporadic
Parkinson disease (18), and Alzheimer pathology in mice and
humans (19), possibly due to its role in neurite outgrowth,
learning, andmemory (20). Taken together, these studies reveal
that GRK5 is implicated in many different human diseases and
may provide an important therapeutic target in the treatment
of cardiovascular disease, neurological and metabolic disor-
ders, and cancer.
Although it is important to understand the in vivo function of
GRKs, it is also important to understand the mechanisms that
mediate GRK function. Significant insight into GRK function
has come from detailed biochemical and biophysical analysis.
This has included defining important functional domains,
including detailedmapping of interfaces such as GRK2 interac-
tion with Gq (21) and G (22) and GRK5 interaction with
Ca2/calmodulin (23). Such studies have been greatly comple-
mented by x-ray crystallography, and structures for GRK1 (24),
GRK2 (25), GRK2/G12 (25, 26), GRK2/G12/Gq (27), and
GRK6 (28) have provided important insight. These structures
reveal that the RH, catalytic, and C-terminal domains are in
extensive contact and help to hold the kinase domain in an
inactive open conformation. Several studies suggest that an
N-terminal -helical domain plays an important role in regu-
lating catalytic domain closure via a process that is likely regu-
lated by receptor binding (29–31). Indeed, this domain has
been observed in one crystal form of GRK1 (24, 31) as well as in
GRK6 in complex with either sangivamycin or AMP (30) and
appears to stabilize catalytic domain closure. Although crystal-
lography has provided significant insight on GRK1, -2, and -6,
there have been no studies to date on the structural analysis of
GRK5.
Here, we use x-ray crystallography to better understand the
structure and function of GRK5. We find that human GRK5
shares significant structural similarity to other GRKs, albeit
with some unique aspects. In contrast to crystal structures of
GRK1 and GRK6, GRK5 is a monomer in the crystal and con-
tains a well ordered kinase domain C-tail that includes interac-
tions between the active-site tether and boundnucleotide. Such
studies have high significance for understandingGRKs andhow
structure/function changes might mediate pathological conse-
quences.Moreover, these studies should set the stage for devel-
oping strategies to specifically regulate GRK5 function in the
treatment of disease.
Experimental Procedures
Materials—Sangivamycin, ADP, AMP-PNP, and phosphati-
dylcholine (soybean type II-S) were purchased from Sigma, and
[-32P]ATP was from PerkinElmer Life Sciences. Crystalliza-
tion screening reagents were purchased from Hampton
Research (Aliso Viejo, CA).
Protein Expression and Purification—The site-specific
mutants GRK5-K215R andGRK5-R470Awere generated using
the QuikChange site-directed mutagenesis kit (Agilent) and
verified by DNA sequencing. The Bac-to-Bac Baculovirus
Expression System (Invitrogen) was used to generate baculovi-
ruses to express human full-length wild-type GRK5, GRK5-
R470A, and kinase-dead GRK5-K215R in Sf9 insect cells. The
recombinant proteins were purified as described previously
with some modifications (32). Briefly, cells were harvested by
low speed centrifugation 48 h after infection, and the cell pellet
was resuspended in lysis buffer (20 mM Hepes, pH 7.2, 250 mM
NaCl, 5mM EDTA, 1mM phenylmethylsulfonyl fluoride, 10M
leupeptin, 3 mM benzamidine, and 0.02% Triton X-100). Cells
were lysed using a Brinkman Polytron (two times for 30 s at
25,000 rpm) followed by high speed centrifugation to remove
cell debris. The supernatantwas diluted 4-foldwith bufferA (20
mM Hepes, pH 7.2, 2 mM EDTA, 0.02% Triton X-100, 1 mM
dithiothreitol (DTT)) and applied to an SP-Sepharose cation-
exchange column. The column was washed and eluted with a
50–750 mM linear NaCl gradient in buffer A. GRK5 peak frac-
tions were pooled, dilutedwith buffer A, loaded onto a heparin-
Sepharose 6 FF affinity column, and eluted with a 200–800mM
linear NaCl gradient in buffer A. GRK5-containing fractions
were pooled, diluted with buffer B (20 mMHepes, pH 7.2, 1 mM
DTT), and injected onto a 1-mlMono S cation-exchange FPLC
column. Proteins were eluted with a 200–700 mM NaCl linear
gradient in buffer B, and fractions containing GRK5 were com-
bined, diluted to 200 mMNaCl with buffer B, concentrated in a
50-kDa molecular mass cutoff filter (Millipore Corp.) to 20
mg/ml, aliquoted, and stored at 80 °C. The yield of pure
GRK5was 2–5mg/liter of Sf9 cells with protein purity95% as
analyzed by SDS-PAGE.
Crystallization—Prior to crystallization, 8 mg/ml GRK5
(120 M) was incubated for 2 h with 4 mM AMP-PNP and 2
mM MgCl2 (GRK5AMP-PNP complex) or 0.4 mM sangivamy-
cin and 0.2 mM MgCl2 (GRK5sangivamycin complex). Initial
robotic screening for crystallization conditions was performed
in a 96-well format using crystallization kits from Hampton
Research. Protein droplets were prepared by mixing 0.4 l of
protein sample with 0.4 l of reservoir solution and equilibrat-
ing against 60 l of reservoir solution as a sitting drop at 4 °C.
Several conditions under which crystals appeared were further
optimized using the hanging-drop vapor-diffusionmethod and
increasing the droplet size and reservoir volume by 5–8-fold,
varying the concentration of precipitants and salts at different
pH values. The complexes crystallized under similar conditions
(AMP-PNP: 0.2 M NaCl, 0.1 M BisTris, pH 6.5, 20% w/v PEG
3350; sangivamycin: 0.15MNaCl, 0.1 MBisTris, pH 5.5, 21%w/v
PEG3350). The best single diffracting crystals were obtained by
micro-seeding. GRK5 crystals appeared within 3 days and grew
over the course of 2–3 weeks with tetragonal bipyramidal mor-
phology. SDS-PAGE analysis of a dissolved crystal revealed full-
length GRK5. Crystals were cryoprotected using the reservoir
solution supplemented to 35% PEG 3350 and flash-frozen in
liquid nitrogen.
Data Collection, Structure Determination, and Refinement—
Diffraction data for crystals were collected at beamline X6A at
the Brookhaven National Synchrotron Light Source (NSLS) on
an Area Detector System Corp. Quantum-270 detector using
an x-ray wavelength of 1.0 Å and 0.2° oscillations under a
constant stream of liquid nitrogen maintained at 100 K. The
best crystals for GRK5AMP-PNP and GRK5sangivamycin
complexes diffracted to 1.8 and 2.1 Å, respectively. Diffraction
data for both datasets were processed and scaled to primitive
tetragonal space group P43212 using HKL2000 suite (Table 1)
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(33). The ligand-bound structures of GRK5 were solved by
molecular replacementwith Phaser (34) using two fragments of
the GRK6 crystal structure (PDB code 2ACX) as the search
model, corresponding to residues 30–179 and 180–507 (kinase
domain). One copy of the GRK5 molecule was located in the
asymmetric unit, which results in an estimated solvent content
of 43%. The model was subjected to iterative cycles of posi-
tional refinement and isotropic B-factor refinement using five
TLS groups in Phenix.refine (35) aswell asmanualmodel build-
ing using Coot (36). To ascertain N-terminal residues 15–23
and a few loop regions of the model, omit-maps and feature-
enhanced maps were calculated using PHENIX. Mg2 ion,
AMP-PNP, and sangivamycin were refined into their corre-
sponding electron density as identified by difference maps.
The final refined models for GRK5AMP-PNP and GRK5
sangivamycin have Rwork/Rfree of 17.2/20.4 and 16.8/23.1%,
respectively (Table 1). The Rfree set was calculated using ran-
domly selected reflections over 14 thin resolution shells. Mol-
Probity (37) evaluation of main chain geometry suggests that
98.3% of residues occupy favored regions of the Ramachan-
dran plot, with no outliers. The validity of refined structure
models to the unmerged diffraction data was assessed using the
correlation coefficient of half-datasets, CC*, using PHENIX.
Also, CC*, CCwork, and CCfree were calculated for the final
deposited structures in PHENIXand suggest that the structures
were not over-fitted (Table 1) (38). Coordinates were deposited
in RCSB structure database with PDB accession codes 4TND
and 4TNB for GRK5AMP-PNP and GRK5sangivamycin com-
plexes, respectively.
Structure Analysis—Structural superpositions were per-
formed using the secondary structure matching algorithm in
Coot (36, 39) and PDBeFold server (39) along with r.m.s.d. cal-
culations and distance deviation analysis between regions.
Domain hinge analysiswas carried out using programDynDoM
(40). All ribbon diagrams and surface representations in this
work were generated using PyMOL (41). Nonlinear Poisson-
Boltzmann electrostatic calculations were performed using
APBS Tools plugin in PyMOL (42). Angles among superim-
posed regions were calculated using phenix.angle script of
PHENIX 1.9–1692 (43). GRK5 intramolecular interactions and
interactions with ligand were mapped using Ligplot plus (44)
and PDBePISA server (80).
Analytical Ultracentrifugation—GRK5 was diluted in 20 mM
Hepes, pH 7.2, 200 mM NaCl, 1 mM DTT to a concentration of
15Mand subjected to analytical ultracentrifugation analysis in
a Beckman ProteomeLabXL-I analytical ultracentrifuge in sed-
imentation velocity mode. GRK5 (400 l) and reference buffer
(420l) were loaded into a two-sector 1.2-cm path length Epon
centerpiece sample cell. The runs were performed at fixed
speed of 50,000 rpm1 at a constant temperature of 4 °C, and
absorbance values were collected at a fixed wavelength of 276
nm. The partial specific volume of GRK5 (v), solvent density,
and relative viscosity values in buffer solution along with theo-
retical molecular mass were calculated using SEDNTERP Ver-
sion 1.09 (45). The resulting datawere fitted to a continuous c(s)
distribution model in program SEDFIT (46) and an estimated
molecular mass was obtained. The fitted data were visualized
and presented using program GUSSI (University of Texas
Southwestern).
Size-exclusion Chromatography—The apparent molecular
mass of GRK5 was analyzed by size-exclusion chromatography
on a Superose 12 16/60 column in 20 mM Hepes, pH 7.2, 200
mMNaCl, 1mMDTT. The columnwas calibrated using protein
standards for cytochrome c (12.4 kDa), carbonic anhydrase (29
kDa), albumin (66 kDa), alcohol dehydrogenase (150 kDa),
-amylase (200 kDa), and blue dextran (2000 kDa) from the gel
filtration molecular weight markers kit (Sigma).
Circular Dichroism—Thermal unfolding of GRK5 and
ligand-bound complexes was monitored by recording varia-
tions in ellipticity at 223 nm as a function of temperature in
1.0 °C increments from 20 to 70 °C using a Jasco J-810 spectro-
polarimeter equipped with a Peltier temperature control sys-
tem. GRK5 at a final concentration of 5Mwasmeasured using a
0.1 cm quartz cuvette (Starna Cells, Inc.) in phosphate-buffered
saline solution (3.2mMNa2HPO4, 0.5mMKH2PO4, pH 7.4, 135
mM NaCl), 0.4 mM ligand, 2 mM MgCl2, and 0.4% dimethyl
sulfoxide.
GRK5 Autophosphorylation Assays—Autophosphorylation
of GRK5 and GRK5-K215R was detected using [-32P]ATP.
GRK5 and GRK5-K215R at concentrations of 0.12 and 0.6 M,
respectively, were incubated for 2 or 60min in 20mMTris-HCl,
pH 7.4, 5 mM MgCl2, 30 mM NaCl, 0.5 mM EDTA, 100 M
[-32P]ATP (2000 cpm/pmol), and 0.85 mg/ml soybean phos-
phatidylcholine vesicles at 30 °C. Reactions were stopped by
addition of SDS loading buffer, and samples were run on SDS-
PAGE, and the gel was stained with Coomassie Blue, dried, and
visualized by autoradiography.
Michaelis-Menten Kinetic Analysis—Km, Vmax, and kcat val-
ues for ATP were determined by varying ATP concentrations
from 2 to 200 M in reactions containing 10 M rhodopsin
(bleached for 5 min) and either 50 nM WT GRK5 or GRK5-
R470A in 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 30 mM NaCl,
0.5mMEDTA, and 4000 cpm/pmol [-32P]ATP. Reactions pro-
ceeded for 2 min at 30 °C in room light and were stopped with
SDS sample buffer. Rhodopsin phosphorylation was quantified
by measurement of 32P incorporation into rhodopsin after
SDS-PAGE as described previously (32). Reaction velocities at
the various ATP concentrations were fit to theMichaelis-Men-
ten equation using GraphPad Prism.
Results and Discussion
Crystal Structure of GRK5—Previous studies suggest that the
crystallization of ligand-free GRKs is very difficult because only
an8 Å crystal structure of apo-GRK1 has been reported (24).
Thus, we initially focused on using nucleotides to stabilize
GRK5 and facilitate crystallization. Circular dichroism was
used to investigate the structural stability of apo- and nucle-
otide-bound GRK5. Thermal unfolding of ligand-free GRK5
yielded an apparent melting temperature (Tm) of 31.5 °C,
although the addition of nucleotides such as ADP, AMP-PNP,
and sangivamycin resulted in an increase inTm, consistent with
stabilization (Fig. 1A). Sangivamycin, a potent nucleoside inhibi-
torofproteinkinases (47), increased theTmby5.5 °C (Tm37 °C),
ADP by 2.5 °C (Tm  34 °C), AMP-PNP by 1.5 °C (Tm  33 °C),
andAMPhad no effect (Tm 31.5 °C). Thus, sangivamycin bind-
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ing induces significant stabilization ofGRK5,whereas the effect of
other nucleotides was less prominent.
Screening full-length human GRK5AMP-PNP and GRK5
sangivamycin complexes led to diffracting crystals of tetragonal
bipyramidal morphology (Fig. 1B). The data collection and
refinement statistics are listed in Table 1. Structures of AMP-
PNP and sangivamycin-boundGRK5were solved to 1.8 and 2.1
Å resolution, respectively, and refined to Rwork/Rfree values of
17.2/20.4% (GRK5AMP-PNP) and 16.8/23.1% (GRK5sangiva-
mycin) at given resolution. Both ligand-bound complexes were
crystallized with nearly identical unit cell dimensions, crystal
packing arrangement, and space group. The domain organiza-
tion of GRK5 includes N-terminal -helical, calmodulin/PIP2
binding and RH domains, a central kinase domain, and a C-ter-
minal region that includes a portion of the RH domain and a
second calmodulin/PIP2 binding domain (Fig. 1C). The crystal
structures revealed a refined model lacking 14 N-terminal and
47 C-terminal residues with residues 15–543 clearly resolved,
FIGURE 1. Atomic structure of GRK5. A, thermostabilization of GRK5 induced by different ligands. Stability of GRK5 against thermal denaturation was
monitored by circular dichroism measurement of changes in the ellipticity intensity at 223 nm as a function of temperature. The measurements were
performed at 5 M GRK5 in the absence (apo-GRK5) or presence of 0.4 mM ligand. B, GRK5AMP-PNPMg2 crystals were grown at 4 °C to dimensions 0.04
0.04 0.12 mm. The crystals show bipyramidal morphology in contrast to rod-like thin plate crystals of its close homolog GRK6 (28). C, domain organization
and important functional regions of GRK5. The RH domain is shown in blue, the catalytic domain in yellow (N-lobe) and orange (C-lobe), and the C-tail of kinase
domain in purple. The two clusters of positively charged residues at the N and C terminus encompass GRK5 CaM- and PIP2-binding sites (magenta). N-terminal
amphipathic -helix is in green. Autophosphorylation sites on the C-tail of the kinase domain are indicated by yellow circles. D, ribbon representation of
GRK5AMP-PNP crystal structure. Full-lengthGRK5(1–590)was crystallized, and residues 15–543 are clearly resolved (the first and last residues are labeled). The
color coding is the same as in C. AMP-PNP ligand and Mg2 are shown as sticks and black sphere, respectively.
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including the kinase domain C-tail, which is not visible in most
GRK structures (Fig. 1D). Mass spectroscopic analysis reveals
that the GRK5 used in crystallography is intact and lacks any
post-translational modifications except for some very minor
phosphorylation at the extreme C terminus (data not shown).
This reveals that the N- and C-terminal regions missing from
the structure are disordered and suggests high flexibility of
these regions, a property common to most GRK crystal
structures.
Overall, the crystal structures of AMP-PNP and sangivamy-
cin-bound GRK5 were nearly identical (r.m.s.d. 0.35 Å), with
minor changes in the structural arrangement of the kinase-ac-
tive site (discussed below). This is in strict contrast to GRK6
(70.4% sequence identity to GRK5), which adopts distinct con-
formations in the presence ofAMP-PNP (28) and sangivamycin
(r.m.s.d. 1.94 Å) (30). The observed difference between GRK5
and GRK6 is likely dictated by structural restraints imposed by
crystal contacts, which appeared to be ligand-independent in
TABLE 1
Crystallographic data collection and refinement statistics
GRK5AMP-PNP GRK5sangivamycin
Data collection statistics
X-ray source NSLS beamline X6A NSLS beamline X6A
X-ray detector ADSC Q270 CCD ADSC Q270 CCD
Wavelength (Å) 1.0 0.98
Space group P43212 P43212
Resolution (Å) 50.00–1.80 (1.83–1.80)a 50.00–2.1 (2.14–2.10)
Unit cell dimensions (Å) a, b 62.975, c 292.644 a, b 62.676, c 292.201
Angles , ,  90.0 , ,  90.0
Solvent content (%)/VM (Å3/Da) 43.8/2.19 43.1/2.16
Molecules/asymmetric unit 1 1
Total reflections 1,877,337 164,745
Unique reflections 52,751 (1625) 28,355 (525)
Multiplicity 35.6 (7.9) 5.8 (1.3)
Completeness (%) 94.2 (59.7) 81.7 (31.5)
Mean I/(I) 50.81 (1.17) 13.06 (1.03)
Wilson B-factor (Å2) 26.48 29.75
Rmergeb 0.09155 (0.8292) 0.122 (0.502)
Rmeasc 0.0928 (0.905) 0.132 (0.668)
Rpimd 0.015 (0.292) 0.049 (0.437)
CC1⁄2 e 1.0 (0.762) 0.994 (0.643)
Refinement statistics
Resolution (Å) 47.73–1.802 (1.867–1.802) 47.57–2.113 (2.188–2.113)
No. of reflections 1,876,659 (34,381) 164,708 (1716)
Reflections used for Rfree 2459 1999
CC*e 1.0 (0.91) 0.998 (0.902)
Rwork 0.1719 (0.2474) 0.1677 (0.2270)
Rfreef 0.2037 (0.2839) 0.2307 (0.3362)
CCworke 0.969 (0.823) 0.971 (0.836)
CCfreee 0.960 (0.853) 0.937 (0.738)
No. of non-hydrogen atoms 4832 4710
Macromolecules 4290 4290
Ligand 32 22
Water 510 398
Protein residues 529 529
Root mean square deviations from
ideal geometry
Bond length (Å) 0.008 0.008
Angles (°) 1.20 1.20
Ramachandran plot and MolProbity
validationg
Residues in favored region (%) 98.3 98.5
Residues in allowed region (%) 1.7 1.5
Residues as outliers (%) 0 0
Clash score 4.30 7.68
Overall score 1.21 1.42
Average B-factor (Å2)
Model (all atoms) 36.1 36.60
Protein 35.63 36.60
Ligand 32.80 25.83
Water 39.90 37.30
Mg2 ion 42.34
PDB code 4TND 4TNB
a Statistics for the highest resolution shell are shown in parentheses.
b The simple merging R factor for the multiple observations is shown (75, 76).
c Redundancy-independent merging R factor is shown (77).
d Precision-indicating merging R factor is shown (78).
e The CC1⁄2 is the correlation coefficient between two randomly selected half-datasets; CC* is a statistic metric for assessing the effective resolution limits of data and quality
of unmerged data in the context of a refined model; CCwork and CCfree are the standard and cross-validated correlations of the observed intensities to the refined model-
based intensities, for the work and test sets, respectively (38).
f Rfree value is calculated using the small subset of randomly selected reflections (test-set) that are set aside prior to refinement and not used in the refinement of the struc-
tural model (79).
g Data are from Chen et al. (37).
Atomic Structure of GRK5
AUGUST 21, 2015•VOLUME 290•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 20633
 at Thom
as Jefferson U
niversity on M
ay 20, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the GRK5 complexes with AMP-PNP and sangivamycin,
although theGRK6 complexes crystallized in two distinct pack-
ing arrangements and space groups. However, theminor differ-
ences between the two crystal structures of GRK5 may not
reflect the propensity of the kinase to adopt distinct conforma-
tions in solution, because crystal structures often trap the low-
est energy and most stable protein conformation. The absence
of structural restraints imposed by crystal lattice contacts pro-
vides the necessary dynamics in the GRK5molecule in solution
resulting in significant differences in GRK5 stabilization
induced by different ligands (Fig. 1A). However, because both
structures show a high degree of structural identity and likely
trap the most stable conformation of GRK5, we focused our
analysis and discussion on the higher resolution GRK5 struc-
ture co-crystallized with the nonhydrolysable ATP analog
AMP-PNP.
TheGRK5 crystal structure contains features typical for pro-
tein kinases in general and GRKs in particular. The kinase
domain possesses a bilobal-fold with a smaller N-terminal lobe
(N-lobe, yellow) and a larger C-terminal lobe (C-lobe, orange)
(Fig. 1D). The N-lobe consists of a canonical five-strand anti-
parallel-sheet (denoted1–5) forming characteristic groove
and flanking helices B and C. TheGRK5C-lobe is composed
of a two-strand antiparallel -sheet (6-7), located under the
interlobe hinge region, and six-helices (D–I). Fully ordered
AMP-PNP is coordinated within the kinase interlobe cleft, rep-
resenting the kinase-active site. Regulatory C-terminal exten-
sion of the kinase domain (Fig. 1D, purple) is fully ordered in
GRK5 and is found in a position near the RH domain that has
not been observed previously in other GRKs.
The bilobal architecture is also a characteristic feature of
GRK RH domains that are structurally related with the regula-
tor of G protein-signaling proteins (48). One lobe is composed
of helices 4–7 packed in an antiparallel manner to assemble
the GRK5 RH bundle subdomain (Fig. 1D). The GRK5 RH ter-
minal subdomain (second lobe) is by N-terminal helices
0–3, 8–9, and C-terminal 10–11. The RH bundle and
terminal subdomains generate a characteristic V-shaped notch
with two ends forming a contact surface with adjacent kinase
domain N- and C-lobes. The 10-helix of the RH terminal sub-
domain has a large interface with the kinase N-lobe, whereas
hydrophilic residues in the N-terminal ends of 4 (backbone
oxygen of Val92) and 7 (Lys139 and Glu140) interact with the
kinase domain C-lobe via polar contacts with Asn452, Lys454,
andArg455 of theJ helix (at the beginning of the kinase domain
C-tail). Thus, the RH and kinase domains of GRK5 are in inti-
mate contact and establish a close relationship between the two
domains that provides a structural basis for allosteric effects
(e.g. receptor binding and kinase domain closure).
No domain-swapped interface, as is observed in prior struc-
tures of GRK1 and GRK6, was observed in GRK5, and both
ligand complexes crystallized as a monomer in the asymmetric
unit. The C-terminal calmodulin- and PIP2-binding domain
(residues 546–565) (23, 49, 50) is located within the disordered
C-terminal segment, immediately adjacent to the last residue
observed in the structure (Pro543). Thus, this domain appears to
be located near the 1-helix of the RH domain and the N-ter-
minal calmodulin/PIP2-binding region (residues 20–39, col-
ored magenta in Fig. 1, C and D) (23, 51). This suggests close
proximity of these two important domains that mediate GRK5
interaction with phospholipids and calmodulin.
A noticeable divergence in the crystal structures of GRK5
and other GRKs is also observed in the relative position of the
RH and kinase domains. The long axis of the RH and kinase
domain of GRK5 is twisted compared with GRK1, GRK2, and
GRK6 (Fig. 2). DynDoM analysis reveals that the hinge for this
motion is located within the interdomain loop of GRK5 that
connects the9-helix of the RHdomain and the1-sheet of the
kinase domain (Fig. 1D). When the kinase domains are super-
imposed, the RH bundle subdomain demonstrates larger dis-
placement than the RH terminal subdomain, consistent with
the position of the RH bundle subdomain far distant of the
hinge. It moves by 10 Å on average (6 helix) relative to its
position in other GRKs (the kinase domains are superimposed
in Fig. 2). The significance of this observed movement of the
two major domains of GRK5 is not clear, because it mainly
affects the relative arrangement of the RH bundle and kinase
C-lobe domains, regions that are remote from the predicted
membrane- and receptor-binding surfaces. Moreover, no sig-
nificant rearrangement of the contact interface between the RH
and kinase domains of GRK5 was identified, and the individual
structures of the RH subdomains were also changed very little
(r.m.s.d. 0.4–0.9 and 1.4–1.6 Å for terminal and bundle,
respectively, comparedwithGRK1 andGRK6). Thismovement
is also unlikely to be related to the crystallization of GRK5 as a
monomer, because aGRK1-L166Kmutant that crystallized in a
monomeric form lacks this structural feature (52). Interest-
ingly, the 2.4 Å crystal structure of bovine GRK5 in complex
with the GRK-selective inhibitor CCCG215022 (see accompa-
nying paper (81)) also does not have the RH and catalytic
domain rotation observed in our GRK5AMP-PNP and
GRK5sangivamycin structures. This suggests some degree of
structural plasticity in the relative orientation of these two
major domains of GRK5.
GRK5 Is a Monomer Both in the Crystal Structure and in
Solution—GRK1 and GRK6 crystallized as dimers in the asym-
metric unit with the C termini of each molecule mediating a
domain-swapped dimer interface (24, 28, 30). In contrast,
GRK5 is a monomer in the crystal structure. Sequence align-
ment identified a unique Pro529 in the C-terminal region of
GRK5 that is not present in other GRKs (Fig. 3A). Pro529 causes
a kink in the polypeptide chain of the C terminus and bends it
back upon itself. Thus, the direction of the visible segment of
the C terminus (the fragment between Asn530 and the last vis-
ible residue Pro543) is changed preventing antiparallel align-
ment of the C termini, which were found to stabilize the dimer
interface in other GRKs. Arg169 is at a key position to support
this architecture and packs against the C-terminal portion of
GRK5 with its guanidinium group forming hydrogen bonds
with the side chain of Asp536, Asn525, and the backbone oxygen
of Val526. In addition, residuesMet165, Phe166, and Arg169 form
a hydrophobic pocket to sandwich Phe527 instead of mediating
a dimer interface as observed in GRK6 (28). A similar packing
arrangement was found in GRK1-L166K, where dimerization
was disrupted by mutation of Leu166 in the hydrophobic dimer
interface resulting in GRK1 crystallization as a monomer (52).
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This confirms that this topology of the C terminus promotes
crystallization of a monomeric form of GRKs.
To determine whether GRK5 also exists as a monomer in
solution, we performed size-exclusion chromatography (Fig.
3B) and analytical ultracentrifugation (AUC) (Fig. 3C). These
experiments revealed molecular masses of 70 kDa by size-
exclusion chromatography and62.4 kDa by AUC under sed-
imentation velocity mode, consistent with a monomeric state,
and no dimer or aggregate forms were detected. There is also
little evidence that other GRKs form dimers in solution,
although some contain a domain-swapped dimer interface in
the crystal structures (28). Although the crystal structure and
in-solution analysis of GRK5 does not exclude dynamic self-
association of GRK5 under some conditions, it demonstrates
that the C-terminal domain-swapped dimer interface typical in
other GRKs is unlikely to be formed in GRK5.
Although our studies suggest thatGRK5 is primarily amono-
mer in solution, there are a few recent reports that GRK5 can
also dimerize. For example, a recent study on the role of GRK5
dimerization in plasma membrane localization demonstrated
that aM165E/F166Emutation disruptsGRK5dimerization and
results in GRK5 redistribution from the plasma membrane to
the cytoplasm (53). Although Met165 and Phe166 mediate a
hydrophobic dimer interface in GRK6 (28), they are involved in
intramolecular stabilization with Phe527 in GRK5 (Fig. 3A).
Although destabilization of this intramolecular interface might
result in a change of membrane-binding properties of GRK5,
the Xu et al. (53) study provides several additional lines of evi-
dence supporting a role forGRK5dimerization in plasmamem-
brane binding. In addition, a role for GRK5 dimerization was
also suggested in actin nucleation (20). Moreover, we find that
GRK5 can undergo intermolecular autophosphorylation in the
presence of phospholipids (see Fig. 6B), also supporting its abil-
ity to dimerize under certain conditions. Taken together, these
studies suggest that GRK5 dimerizationmay be linked to phos-
pholipid binding.
Kinase Domain of GRK5 Adopts a Partially Closed Confor-
mation and Binds Ligands in the Canonical ATP-binding
Pocket—In AGC kinases, the small and large lobes of the kinase
domain are observed to “close” upon binding of nucleotides and
substrate peptides, phosphorylation of the activation loop or, in
PKA, complex formation between catalytic and regulatory sub-
units (54, 55). It is believed that the fully closed conformation of
the kinase domain allows proper alignment of substrate and
nucleotide in the active site needed for effective catalysis (56).
Superposition of GRK5with its close homologGRK6 and the
prototypical AGC kinase PKA reveals an intermediate partially
closed conformation of the GRK5 kinase domain (structural
coordinates of kinase domain C-lobe were superimposed to
observe differences in conformation of N-lobe, indicative of
kinase domain closure) (Fig. 4A). GRK5AMP-PNP adopts a
more closed conformation compared with the open state of
apo-PKA (PDB code 1J3H) and GRK6AMP-PNP (PDB code
2ACX), yet it is somewhat less closed than the fully closed con-
formation of PKA (catalytic subunit of the holo tetrameric
complex; PDB code 3TNP). The catalytic cleft of GRK5 is nota-
FIGURE2.RHdomaindisplacement inGRK5.Comparisonof the structural topologyof theRHandkinasedomains inGRK5AMP-PNPandGRK6sangivamycin
(PDB code 3NYN). Kinase domains were superimposed to reveal an 8.5° rotation of RH domain. The comparison of GRK5 with the GRK1 and GRK2 crystal
structures reveals similar displacements of structural elements within RH domain with largest changes in the RH bundle subdomain (6–13 Å of 6-helix
displacement) (data not shown).
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bly narrower than in apo-PKA and GRK6AMP-PNP, consis-
tent with a more catalytically competent conformation of the
kinase domain. Overall, the conformation of the GRK5 kinase
domain closely resembles the relatively closed state observed in
the GRK6sangivamycin structure (PDB code 3NYN), the most
closed structure of a GRK determined to date.
AMP-PNP and sangivamycin both have strong electron den-
sity and low B-factors in the refined GRK5 structure. They
reside in the canonical ATP-binding pocket in a large cleft
formed in the interlobe space of the kinase domain. The purine
ring of the ligands is buried within a hydrophobic pocket in the
active site. Two additional conserved hydrogen bonds with
Thr264 and Met266 of the hinge region fulfill binding for the
adenine base (Fig. 4B). The triphosphate tail is more solvent-
accessible than in the fully closed PKA structure (57) due to
partial opening of the cleft and rising of the P-loop. The ribose
portion of the ligand is partially shielded by a direct contact
with the AST of the C-terminal extension of the kinase domain.
The sangivamycin-binding site largely overlaps the adenine-
and ribose-binding sites of AMP-PNP. AMP-PNP retains only
onemagnesium ion in a tridentate chelation by oxygen atoms of
-, -, and -phosphates as well as Asp329 of the “DLG” motif
(“DFG” in PKA/PKB/PKC) and Asn316 (Fig. 4B), similar to
PKAAMP-PNP (57) and PKBAMP-PNP (58) structures,
although magnesium ions are coordinated in a bidentate fash-
ion by phosphate groups in this case. Magnesium also binds a
catalytic water molecule to fulfill the octahedral coordination
state (59). In theGRK6AMP-PNP structure, Asp329 andAsn316
are displaced due to the more open conformation of the kinase
domain and do not coordinate magnesium, although in the
GRK5sangivamycin complex, the side chain of Asp329 forms
hydrogen bonds with the amide group at the C7 position of
the diazaindole ring of sangivamycin instead of magnesium
coordination.
One characteristic of the protein kinase active state is inter-
action between a conserved glutamate residue from the C-he-
lix and lysine residue from the 3-strand (60). Mutation of this
catalytic lysine residue (Lys215 in GRK5/6, Lys216 in GRK1, and
Lys220 in GRK2) into arginine inactivates GRKs. Lys215 is posi-
tioned by Glu234 to bind - and -phosphates of the ligand in
GRK6AMP-PNP and GRK1ATP (Lys216 and Glu235). In
GRK5AMP-PNP, Lys215 also forms a hydrogen bond with
Glu234, but it lacks contact with the triphosphate tail of the
ligand (Fig. 4C). The triphosphate tail of AMP-PNP in GRK5
adopts a conformationwith the- and-phosphates shifted 1.5
and 4 Å away from Lys215, respectively, as compared with
GRK6AMP-PNP (28) and thus is less buried in the catalytic
cleft (Fig. 4C). The crystal structure of GRK5AMP-PNP was
obtained under low magnesium concentration and therefore
shows electron density for only one magnesium ion. As noted
above, this magnesium ion is coordinated in a tridentate
arrangement by the triphosphate tail in GRK5, although nor-
mally magnesium is coordinated in a bidentate manner by two
phosphate groups of ATP or AMP-PNP. It is possible that the
binding of a second Mg2 (at high magnesium concentration)
would change the triphosphate tail conformation and help to
position it deeper in the active site cleft of GRK5, where it can
interact with Lys215.
The phosphate-binding glycine-rich loop (P-loop) of the
N-lobe is formed by the 1-2 turn and is directly engaged in
binding of the triphosphate tail of ATP when the kinase is in its
active state (full closure of kinase domain) and helps to stabilize
the phosphorylation transition state (61). Because of incom-
plete closure of the kinase domain inGRK5, the P-loop is raised
a bit above the triphosphate tail and is not fully engaged in
phosphate group binding as observed in the fully closed confor-
mation of PKAAMP-PNP (57). P-loop is engaged in coordina-
tion of - and -phosphates, although it is still misaligned with
the -phosphate. However, the P-loop of GRK5 is observed at a
lower position when compared with the open conformations of
apo-PKA (62) and GRK6AMP-PNP (28). Interestingly, the
P-loop of GRK5 seems to be in more intimate contact with the
adjacent B-helix of the N-lobe than in other GRK structures.
Side chains of Glu218, Arg221, and Arg225 residues are situated
on the side of B-helix facing toward the P-loop and form a
network of hydrogen bonds with the last two being directly
bound to the backbone oxygen of Gly196 from P-loop (Fig. 4D).
The adjacent residue Phe197 of the P-loop packs against the
guanidinium group of Arg225 and is engaged in weak cation-
interaction.Overall, these contacts should stabilize the position
of the P-loop. Compared with other GRKs, the interface
between B-helix and P-loop in GRK5 is stronger due to
involvement of both arginines from the B-helix, although in
otherGRKs the interaction is provided only by oneArg residue.
The tight contact between the P-loop and the adjacentB-helix
of the N-lobe provides a basis for synergistic changes within
these two sides of the kinase catalytic groove.
Active-site Tether Is an Integral Part of the Nucleotide-bind-
ing Pocket of GRK5—The C-terminal extension of the kinase
domain (C-tail) is a conserved feature of all AGCkinases (63). It
FIGURE3.GRK5 is amonomerboth in the crystal structure and in solution.A, structural basis formonomeric state ofGRK5. Atomic structures ofGRK5AMP-
PNP (cyan) andGRK6sangivamycin (chain A of dimeric complex PDB 3NYN is shown in pink) were aligned to highlight differences in the topology of the visible
regions of their C termini. GRK5 is oriented from the top of the view in Fig. 1D, and its C terminus is shown inmagenta, and the GRK6 C terminus is in red. The
GRK6 C terminus is domain-swapped; its position is fixed by symmetry-related GRK6 molecule from the dimer complex (data not shown), and the GRK5 C
terminus is alignedagainst its ownRHdomain. Key intramolecular contactsbetween theGRK5C terminus andRHdomain that support the specific architecture
of the C terminus are highlighted in the left box, and the hydrophobic pocket consisting of Met165, Phe166, and Arg169 (RH domain) that retains Phe527 (C
terminus) is highlighted in the right box. Sequence alignment of C-terminal regions of human GRKs indicates unique Pro529 (framed inmagenta) that forms a
kink, thereby hindering a domain-swapped interface in GRK5. Identical residues are boxed in red, and residues showing similarity are in red and grouped in a
blue frame. B, size-exclusion chromatographic analysis of purified GRK5. A Superose 12 16/60 gel filtration column was calibrated using molecular mass
markers, whose elution volumes and relativemolecularmasseswere used to build a calibration curve (inset). GRK5 eluted as a single species consistentwith an
70-kDamonomeric state of the protein. C, sedimentation-velocity profile of GRK5. The top panel shows the raw absorbance (solid circles) collected at 276 nm
with the interval of 40 min together with corresponding fitted data (solid line) plotted as a function of radial position. The low values (	 5% of signal) for
residuals confirm fidelity of fit between raw and fitted data. The monophasic sedimentation boundaries suggest that GRK5 exists as a monodisperse single
species in solution. The bottompanel shows the fitted distribution of the apparent sedimentation coefficient calculated for GRK5 is 2.6 S, which corresponds to
an estimated molecular mass of62.4 kDa, consistent with a monomer of 67.8 kDa (theoretical molecular mass).
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spans the kinase domain C-lobe (C-lobe tether; residues 451–
467 in GRK5), active site (AST; residues 468–473), and N-lobe
(N-lobe tether (NLT); residues 474–502) (Fig. 5A). The C-tail
plays a regulatory role in AGC kinases, acting either as a cis-
interacting regulatory element with direct influence on kinase
activity or as a scaffold for trans-interacting elements that dock
on the C-tail and modulate AGC kinase activity (63).
TheAST segment of the C-tail regulates the catalytic cycle of
substrate phosphorylation in AGC kinases and helps to control
entry and exit of nucleotide in the kinase-active site (so-called
“nucleotide gate”) (54). It is typically disordered in the absence
of nucleotide but becomes an integral part of the ATP-binding
site when nucleotide is bound and the kinase domain is closed
(64). A conserved Phe-Asp-Asp-Tyr (FDDY) motif (residues
327 to 330 in PKA) in theAST, particularly Phe327 andTyr330, is
part of the hydrophobic pocket that anchors the adenine and
ribose rings of ATP in PKA and many other AGC kinases (Fig.
5B) (63). Replacement of these residues with Ala reduces affin-
ity for ATP and ultimately inactivates the enzyme (65, 66). In
GRKs, the FDDYmotif is not conserved, and the AST fragment
does not coordinate nucleotide even when fully ordered as in
the GRK6/sangivamycin structure (30). However, we observed
a direct contact of the AST segment to the ribose ring of AMP-
PNP and sangivamycin in GRK5, which resembles the AST-
nucleotide interaction observed in PKA and PKB (Fig. 5B).
The AST spans the active site with the side chain of Arg470
intruding into the nucleotide-binding pocket of GRK5 to
hydrogen bond with the ribose ring of AMP-PNP. Guani-
dinium group of Arg470 directly interacts with 3-OH of the
AMP-PNP ribose ring, although analogous interaction of
Tyr330 of PKA requires an active-site conservedwatermolecule
to mediate AST interaction with 2-OH of the ribose ring (Fig.
5B). Importantly, Arg470 also mediates a hydrogen bond net-
work and plays a central role in bridging the C-tail with the
N-lobe (Arg470 backbone oxygen and guanidinium group inter-
act with Arg190 and Leu192 of the 1-strand, respectively) and
the hinge region (Arg470 backbone amide binds to Asn267) (Fig.
5C). Although GRK5 adopts an intermediate state with the
structural elements of the kinase domain not fully aligned for
phosphotransfer, the contact interface between Arg470 and
other parts of the kinase domain facilitate its closure. Interest-
ingly, in theGRK6sangivamycin structure, the orderedN-he-
lix and Arg190 of 1-strand were at the center of the interface
stabilizing the closed state of the kinase domain (30). We spec-
ulate that Arg470 has a similar role in GRK5, which also adopts
a partially closed conformation even in the absence of N-helix
ordering. Furthermore, Arg470 seems to have an even more
prominent role in the GRK5sangivamycin complex compared
withGRK5AMP-PNP, because its side chain is bent toward the
C-lobe, and the guanidinium group also hydrogen bonds with
Asp270 of C-lobe (Fig. 5C), in addition to the observed interac-
tion to the ribose ring in the AMP-PNP complex. Thus, tighter
contact between N- and C-lobes provided by AST in
GRK5sangivamycin might better stabilize the closed state of
the kinase domain, which is in agreement with increased ther-
mostability demonstrated in our biophysical studies (Fig. 1A). It
might also explain the slight lowering of the P-loop in compar-
ison with GRK5AMP-PNP (Fig. 4A, inset), although the lack of
phosphate groups in sangivamycin as compared with AMP-
PNP is a more compelling argument in this case. Similar low-
ering of P-loop was observed in PKA complex with adenosine
(similar to sangivamycin it lacks a triphosphate tail; PDB code
1FMO) as compared with PKAAMP-PNP crystal structure
(PDB code 4DH3).
Interestingly, despite a large sequence difference between the
AST segments of PKA and GRK5, it maintains similar spatial
arrangement of intramolecular contactswith nucleotide andN-
and C-lobes (Fig. 5D). It appears that the guanidinium group of
Arg470 in GRK5 occupies a similar locus as conserved catalytic
water in PKA (red sphere in Fig. 5D), which was shown to form
a network of interactions with nucleotide (links Tyr330 to
2-OH of ribose ring), N-lobe (through the carbonyl oxygen of
Leu49 of P-loop), and C-lobe (through the carboxylate of
Glu127) in a fully closed state of catalytic subunit in PKA. Sim-
ilar interactions are observed inGRK5 butwithout assistance of
the catalytic water molecule. Also, backbone carbonyl and
amide of Arg470 in GRK5 form similar contacts with the hinge
and the N-lobe as observed for Asn326 and Asp329 of the AST
fragment in PKA (Fig. 5D). Thus, Arg470 in the GRK5 AST
maintains a similar set of contacts as distinct AST residues in
PKA. Structural conservation of these contacts in GRK5 sug-
gests an essentially similar role of AST for kinase domain clo-
sure that was well characterized in PKA (59, 63).
To further assess a role for C-tail interaction with nucleotide
in GRK5, we replaced Arg470 with alanine and compared cata-
lytic parameters of mutant and wild-type GRK5. GRK5-R470A
FIGURE 4.GRK5 kinase domain adopts a partially closed conformation. A, structural alignment of the GRK5 kinase domain with the open, partially closed
(intermediate), and fully closed conformations of the kinase domains from PKA (top panel) and GRK6 (bottom panel) reveals that the GRK5 kinase domain is in
an intermediate, partially closed conformation. Structural coordinates of the kinase domain C-lobe were superimposed to reveal conformational changes in
the N-lobe. The changes in the N-lobe that are indicative of kinase domain closure (B, C, K, and P-loop) are shown with red arrows. Only AMP-PNP (stick
model) from GRK5, which indicates active site of kinase, is shown. Inset, GRK5 in complex with AMP-PNP or sangivamycin (active site view) was aligned based
on their C-lobes to highlight 1 Å lowering of P-loop (slightly more closed conformation) in the sangivamycin complex compared with the AMP-PNP complex.
B, ligand-binding pockets for AMP-PNP and sangivamycin in GRK5. Left panel, view of catalytic cleft with residues that form ligand-binding site presented in
stick model. The one magnesium ion (black sphere) is retained in tridentate manner by oxygen atoms of -, -, and -phosphates of AMP-PNP with the side
chains of Asp329 (DLGmotif) and Asn316 also involved in its coordination. The catalytic H2Omolecule that mediates Asn
316 and Asp329 contact with Mg2 and
the triphosphate tail is shown as a red sphere. Nitrogen, oxygen and phosphorus atoms are colored blue, red, and orange, respectively. Right panel, two-
dimensional schematic diagrams of GRK5 interactionswithAMP-PNP and sangivamycin. Residues that formhydrogenbonds (dotted lines) with the ligands are
shown in ball-and-stick with the interatomic distances shown in Å. The spoked arcs represent residues making van der Waals interactions with the ligand.
Diagrams were generated with Ligplot plus. C, differences in conformation of triphosphate tail of AMP-PNP in crystal structures of GRK5 and GRK6 (PDB code
2ACX). The conserved residue Glu234 (C-helix) hydrogen bondswith another conserved residue, Lys215 (3-strand), in GRK5 andGRK6 (shown as cyan dashed
line between GRK5 residues). Lys215 pairs with -phosphate of AMP-PNP in GRK6 (yellow dashed lines), although -phosphate in GRK5 is positioned far from
Lys215. D, P-loop/B-helix binding interface in GRK5AMP-PNP structure. Main chain oxygen of Gly196 (P-loop) is engaged in hydrogen-bonding network,
including Arg225, Arg221, and Glu218 of B-helix (N-lobe). Residues involved in the binding interface are shown in ball-and-stick representation, and AMP-PNP
and Mg2 are shown as stick and black sphere, respectively.
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did not demonstrate a dramatic effect on Michaelis-Menten
kinetics for ATP, albeit catalytic efficiency (kcat/Km) was
reduced by 22% compared with WT GRK5 (Fig. 5E). Interest-
ingly, the effect was primarily due to a change in Vmax (Kcat),
although the Km value was unchanged. This suggests that the
contribution of Arg470 to nucleotide binding is minimal (no
effect onKm), although it facilitates theGRK5 catalytic reaction
(effect on kcat andVmax). In agreement with this, a lower rate of
substrate phosphorylation by GRK5-R470A was revealed in
time courses of rhodopsin and tubulin phosphorylation by
GRK5 (data not shown). Although a mechanistic understand-
ing of this at the molecular level requires additional studies,
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Arg470 interaction with the ribose ring might help to stabilize
the orientation of nucleotide within the active site needed for
effective catalysis. Another possible interpretation can be
related to a potential role of Arg470 in facilitating ADP release,
the rate-limiting step in product turnover by protein kinases
(67). The AST is engaged in nucleotide coordination and is
found in close proximity to the kinase-active site in fully closed
(active) conformation of PKA, although it is further away from
the active site in the intermediate and open states (68). Thus,
the AST might provide an additional driving force for ADP
release when the catalytic cycle is complete and the enzyme
adopts a more open conformation with the AST moving away
from the active site and pulling out the nucleotide from the
kinase-binding pocket. If true, AST interaction with nucleotide
should increase nucleotide off-rate, which is in agreement with
observed higher catalytic turnover rate forATPofWTGRK5 as
compared with GRK5-R470A where AST is disengaged.
Thus, the kinase domain C-tail of GRK5 is fully ordered, and
its AST fragment directly interacts with nucleotide in the cata-
lytic cleft thereby playing a similar nucleotide gate role as in
many other AGC kinases. In contrast, the AST in GRK1 (24)
and GRK6 (28) is disordered and not part of the nucleotide-
binding pocket, despite the active site being occupiedwithADP
or ATP (AMP-PNP). AST in GRK6sangivamycin is ordered,
mainly due to interactions with N-helix, but it is not involved
in coordination of the ligand. Available crystal structures of
GRK2 lack electron density for nucleotide in the nucleotide-
binding pocket, although GRK2-G was crystallized in the
presence of ATP, and therefore, it is not clear whether the AST
is involved in nucleotide coordination. However, the AST is
partially ordered in a structure of GRK2 bound to the serotonin
reuptake inhibitor paroxetine,mainly due to a fewweak van der
Waals contacts with the piperidine B ring of paroxetine (69).
Thus, a role of AST in other GRKs is not clear. Interestingly,
Arg470 is not conserved evenwithin theGRK4 subfamily (His in
GRK4 and Gln in GRK6, see GRK sequence alignment in Fig.
5A); therefore, the contribution of the AST in nucleotide coor-
dination could be unique to GRK5.
StructuralMobility of the Kinase Domain C-tail—The kinase
domain C-tail (Fig. 5A) is generally disordered to a different
degree in GRK crystal structures and has only been completely
modeled in partially closed GRK1ATP (24) and GRK6
sangivamycin (30). Although the GRK5 crystal structure also
adopts a partially closed state, there are marked differences in
the position of the C-tail and its intramolecular contacts. The
entire kinase domain C-tail of GRK5 is well ordered with con-
sistently low B-factor values (32.0 Å2 for the C-tail versus 35.6
Å2 for an entire ligand-bound model, see Table 1) compared
with the structures of GRK1 and GRK6 (data not shown).
Extensive intramolecular and intermolecular (crystal packing)
contacts account for the low B-factors of the C-tail in GRK5.
Fragment 470–475 and K-helix are stabilized through crystal
contacts to the adjacent GRK5 molecule in the crystal lattice.
The AST is also stabilized via hydrogen bonding to nucleotide,
whereas the NLT is anchored in the binding pocket formed by
1–5 strands of theN-lobe. Comparing its position relative to
the N-lobe in GRK1 and GRK6, the GRK5 NLT, including the
autophosphorylation sites, moves more than 20 Å away from
the close proximity of the catalytic cleft and occupies a new
position close to theRHdomain (Fig. 6A). InGRK6sangivamycin,
the AST forms a typical “tail loop” (Fig. 6A, inset) interacting with
N-helix (which is disordered in GRK5). The tail loop (“AST
loop”) isnot formed inGRK5,and insteadofbinding to theN-he-
lix, the AST region participates in nucleotide coordination with
Arg470. Moreover, unwinding of the tail loop results in displace-
ment ofAST residues upward from the kinase-active site (e.g. 12Å
shift of Tyr473 in GRK5 relative to its the N-lobe in GRK5 (29
amino acids, residues 474–502) as compared with GRK6 (23
amino acids, residues 480–502) and GRK1 (26 amino acids, resi-
dues 481–506).This enables theNLTto followanovel path andbe
positioned inside theN-lobe-sheet groove, a site that isnotoccu-
pied inGRK1 andGRK6. This newposition of theNLT resembles
the position of the NLT in PKA/PKB/PKC, which also span the
N-lobe groove, although the NLT is not as deeply buried as in
GRK5.
The NLT in PKA/PKB/PKC serves as a docking site for an
upstreamkinasePDK1thatmediatesPKA/PKB/PKCphosphor-
ylation and positions the C-helix within the ATP-binding
pocket (63). In the GRK1 and GRK4 subfamilies, the NLT con-
tains adjacent autophosphorylation sites that appear to regulate
GPCRphosphorylation (Fig. 5A) (2).We examined themobility
of theNLTsegmentbyanalyzing intramolecularautophosphor-
ylation of GRK5 (Fig. 6B). In addition, we also tested the ability
of wild-type GRK5 (WT) to phosphorylate a kinase-dead
FIGURE 5. AST is an integral part of the nucleotide-binding pocket of GRK5. A, sequence alignment of human GRK kinase domain C-terminal extension.
GRK5 autophosphorylation sites (Ser484 and Thr485) are indicated as is Arg470 in the AST (framed inmagenta), which forms a direct contact with the nucleotide
in GRK5. Identical residues are boxed in red, and residues showing similarity are in red and grouped in a blue frame. CLT, C-lobe tether. B, interaction of ASTwith
nucleotide in the active site of GRK5 and PKA as viewed from above the P-loop. Phe327 and Tyr330 (AST) mediate van derWaals interactions with the AMP-PNP
purine and2-OHof the ribose ring (via active-site conservedwater), respectively, in PKA, and theguanidiniumgroupofArg470 hydrogenbondswith the 3-OH
ofAMP-PNP ribose ring inGRK5. The1–3 strandswere removed for clarity.C,hydrogenbondnetwork stabilizedbyArg470 inGRK5 complexeswithAMP-PNP
and sangivamycin. Arg470 mediates interactions with the nucleotide (via ribose ring of AMP-PNP and sangivamycin), N-lobe (via Arg190 and Leu192), hinge (via
Asn267), and C-lobe (via Asp270 in GRK5sangivamycin). Thus, Arg470 likely plays an important role in the interface that promotes closure of the kinase domain
and regulates nucleotide entry/exit. The GRK5AMP-PNP structure lacks direct Asp270 (C-lobe) contact with Arg470 and ribose (mediated by catalytic water
molecule in this case) that is observed in GRK5sangivamycin andmight explain the slightly less closed conformation of the kinase domain in GRK5AMP-PNP.
D, interactionswithin the catalytic siteof PKAbound toAMP-PNPand substratepeptide (magenta) analogous toArg470 inGRK5. Side chainofArg470 ismodeled
in yellow ball-and-stick representation to show its position in GRK5 relative to PKA (kinase domains of GRK5 and PKA are aligned). Active site conserved water
molecule (red sphere) that connects Tyr330 to the ribose ring of AMP-PNP in PKA hydrogen bondswith Leu49 (1-strand of N-lobe) and the ribose ring hydroxyl
group, thus resembling the guanidiniumgroup of Arg470 interactionswith Leu192 and 3-OH of the AMP-PNP ribose in GRK5.Moreover, the AST/hinge and the
AST/N-lobe contacts provided by backbone carbonyl and amide of Arg470 in GRK5 are similar to Asn326 (AST)/Ala124 (hinge) and Asp329 (AST)/Lys49 (N-lobe)
contacts, respectively, inPKA. Thus, interactionsofASTwith thenucleotideandN- andC-lobes thathelp to stabilize the closed stateof thekinasedomain inPKA
are arranged in a similar manner in GRK5 and PKA. E, effect of R470Amutation onMichaelis-Menten kinetics for ATP. The kinetic parameters were determined
by incubating 50 nM GRK5, 10M rhodopsin, and 2–200M ATP as described under “Experimental Procedures.” The data are derived from three experiments
and fitted to Michaelis-Menten kinetics using GraphPad Prism.
Atomic Structure of GRK5
AUGUST 21, 2015•VOLUME 290•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 20641
 at Thom
as Jefferson U
niversity on M
ay 20, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
mutant GRK5-K215R (KD) to assess intermolecular autophos-
phorylation. In the presence of ATP and phospholipids, GRK5
undergoes rapid autophosphorylation at Ser484 and Thr485
within the NLT (70). KD and WT GRK5 were incubated sepa-
rately or together for 2 or 60 min, and incorporation of 32P into
GRK5 was evaluated by SDS-PAGE. Autophosphorylated
forms of GRK5 migrate slower, which leads to the appearance
of two shifted bands of partially and fully autophosphorylated
WT GRK5 after 2 min and one band of fully autophosphoryla-
ted WT GRK5 after 60 min. Only autophosphorylation of the
WT enzyme was detected upon 2 min of reaction despite a
5-fold molar excess of KD GRK5, providing evidence for an
FIGURE 6. Structural mobility of the kinase domain C-tail in GRKs. A, comparison of kinase domain C-tail orientation in GRK5 relative to its position
in GRK6 (PDB code 3NYN, upper left), GRK1 (PDB code 3C4W, lower left), and PKA (PDB code 3TNP, lower right) reveals a large displacement of the GRK5
NLT segment compared with GRK1 and GRK6. The GRK5 NLT moves away from the catalytic cleft and occupies a position close to the RH domain with
autophosphorylation sites (red sticks) largely shifted from their position in GRK1 and GRK6 (23 Å and 26 Å, respectively). The structural coordinates of the
GRK5 NLT more closely resemble the conformation of the NLT in PKA (12 Å distance between corresponding positions of autophosphorylation sites,
Ser338 in PKA and Ser484 in GRK5). Inset, upper right, Tyr473, which is conserved in the GRK1 and GRK4 subfamilies, forms a hydrogen bond with the
backbone amide of Asp468 and stabilizes the tail loop (AST loop) in GRK6. In GRK5, Tyr473 shifts 12 Å away from its position in GRK6 and does not stabilize
formation of the AST loop. B, GRK5 is autophosphorylated in an intra- as well as intermolecular manner. GRK5 (WT) and kinase-dead GRK5-K215R (KD)
were autophosphorylated alone or in a WT/KD mixture at a 1:5 molar ratio. The reaction was done in the presence of [-32P]ATP and phospholipid
vesicles at 30 °C for 2 or 60min as described under “Experimental Procedures.” Only intramolecular autophosphorylation ofWTGRK5was observed after
2 min, which demonstrates the mobility of the GRK5 kinase domain C-tail, which can access the active site of GRK5 situated 25 Å away from the
catalytic cleft in the crystal structure. Phosphorylation of the KD mutant was only detected at 60 min when WT GRK5 was present, demonstrating the
ability of GRK5 to autophosphorylate in an intermolecular manner. GRK5 that is fully autophosphorylated (F), intermediately autophosphorylated (I), or
nonphosphorylated (N) is denoted on the right.
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intramolecular reaction (Fig. 6B). TheKDmutant is not capable
of any autophosphorylation, and therefore its phosphorylation
is indicative of intermolecular phosphorylation by WT GRK5.
Phosphorylation of KD mutant was detected after 60 min sug-
gesting that intermolecular phosphorylation of GRK5 also
occurs, albeit with much slower kinetics than intramolecular
autophosphorylation (Fig. 6B). Thus, autophosphorylation of
GRK5 can occur in an intra- as well as an intermolecular man-
ner (cis- and trans-autophosphorylation). Because autophos-
phorylation sites in the NLT are situated relatively far from the
catalytic cleft in the crystal structure of GRK5, intramolecular
autophosphorylation suggests high mobility of this region in
solution. In the crystal structure, mobility of this region is
restricted by crystal packing contacts, although conformational
variability of the C-tail observed in different ligand complexes
of GRKs (either fully or more often partially visible C-tail) also
implies “malleability” of the C-tail.
Molecular Basis of GRK5 Association with the Plasma
Membrane—Severalmechanisms ofmembrane localization are
utilized byGRKs to be in close proximity to their substrates, the
integralmembraneGprotein-coupled receptors. These include
C-terminal prenylation (GRK1 and GRK7), palmitoylation
(GRK4 and GRK6), pleckstrin homology domain binding to
acidic phospholipids and membrane-associated G-subunits
(GRK2 andGRK3), and electrostatic interaction with phospho-
lipids (GRK4–6) (1). Two clusters of basic/hydrophobic resi-
dues within the N- and C-terminal regions appear to play a
primary role in GRK5 association with phospholipids (Fig. 1C).
When oriented as in Fig. 1D, an electrostatic contour reveals a
bipartite distribution of the surface chargewith the top (includ-
ing N- and C-terminal regions) and the right side (N-lobe and
catalytic cleft of kinase domain) of GRK5 abundant in basic
residues, although the RH domain and C-lobe (except for its
active site surface area) are predominantly negatively charged
(Fig. 7A, left center). TheN-terminal membrane-binding deter-
minant (residues 22–35) is part of the positively charged area
on the top of GRK5 and, together with several other basic resi-
dues in theN-lobe and theC-tail of kinase domain that lie in the
same plane, constitutes a largemembrane-binding surface (Fig.
7A). Based on the position of the last visible residue in the struc-
ture (Pro543), the C-terminal membrane-binding determinant
(residues 546–562) should be located in close proximity to the
N-terminal membrane-binding interface and therefore extend
the area of positive charge on the membrane-binding region of
GRK5. Simultaneous anchoring of the N- and C-terminal basic
regions might result in formation of a single broad surface that
promotes stable association of GRK5 with phospholipids (Fig.
7B). Two-dimensional diffusion within the membrane plane
would enable GRK5 to rapidly encounter and dock on an acti-
vatedGPCR (Fig. 7B). This would be followed by kinase domain
closure and proper alignment of the receptor phosphoacceptor
sites (C terminus) onto the C-lobe of the catalytic cleft in a
manner analogous to how substrate peptide docks into the cat-
alytic cleft of PKA, which was used to model substrate binding
for GRK5 in Fig. 7A (C-lobes of PKA and GRK5 were aligned).
Once receptor phosphorylation is complete, GRK5would likely
dissociate from the receptor and possibly the membrane via a
process that may be regulated by GRK5 autophosphorylation
(Fig. 7B). This would be similar to GRK1, where autophosphor-
ylation facilitates dissociation of GRK1 from phosphorylated
rhodopsin (71).
Another aspect ofGRK5 regulation to consider is its ability to
interact with calmodulin (CaM), a ubiquitous Ca2 sensor that
links elevation of intracellular calcium levels with GRK inhibi-
tion. Although the exact mechanism of CaM binding to GRK5
is unknown, previous studies demonstrated that CaM binds to
N- and C-terminal regions of GRK5 (residues 20–39 and 546–
562) (23, 72), which largely overlapwith themembrane-binding
determinants. This leads to the hypothesis that CaM binding
would block GRK5 association with membranes in response to
elevation of intracellular calcium levels and thereby attenuate
GPCR phosphorylation (Fig. 7B).Moreover, CaM enhances the
redistribution of GRK5 from the plasmamembrane to the cyto-
plasm and/or nucleus, where GRK5 targets a different set of
substrates (5). CaM wrapping around an amphipathic -helix
of a target protein represents the canonical binding mode of
CaM (73). Moreover, CaM can induce helical formation when
bound to regions that were previously extended or disordered
FIGURE 7.GRK5 electrostatic surface and amodel for GRK5 binding to phospholipid membranes. A, electrostatic surface potential of GRK5. The surface
potential of GRK5 is depicted from5 (red, acidic) to5 (blue, basic) kT/e, and neutral regions arewhite. The stretch of basic residues is clustered on the top
of GRK5 andmaps the presumedmembrane-binding surface. TheN-terminalmembrane-binding region (residues 22–35) is abundant in Lys residues (labeled)
and is at the core of the interface providing electrostatic interaction of GRK5with negatively charged lipids in the plasmamembrane. A fewpositively charged
residues of the N-lobe and the C-tail of kinase domain might also contribute to electrostatic anchoring of GRK5 onmembranes. It should also be emphasized
that although the C-terminal membrane-binding region (residues 546–562) is not resolved in the GRK5 crystal structure, it is near the last residue that was
observed (Pro543, labeled) and thus should be in the same plane with the N-terminal membrane-binding region likely constituting a common electrostatic
surface for membrane attachment. The electrostatic contour of the kinase-active site also has a basic character. Substrate peptide (yellow stick model) from a
PKAAMP-PNPSP20 complex (PDB code 4DG0) was mapped onto GRK5 C-lobe to model substrate binding into the catalytic cleft of GRK5 (coordinates of
C-lobes of GRK5 and PKAwere aligned). The zoomed-in view demonstrates the peptide orientation relative to AMP-PNP in GRK5. The site of phosphorylation
on the substrate peptide is labeled and is positioned against the-phosphate of AMP-PNP. This illustrates the initial step of the kinase catalytic cycle (substrate
and nucleotide alignment into the kinase-active site). B, structural model depicting binding and CaM-driven dissociation of GRK5 from phospholipid mem-
brane and GPCRs. The model is based on the GRK5 crystal structure, which is oriented relative to the phospholipid surface in a manner that would bring the
N-terminalmembranedomain (residues 22–35) in close contactwith PIP2 in theplasmamembrane. Color coding is the sameas in Fig. 1D. TheGRK5C terminus
(residues 544–590) is incomplete in the crystal structure and therefore unresolved regions are depicted as a gray dashed line, and the C-terminal membrane-
binding region (residues 546–562) is depicted as a gray -helix. The crystal structure of GRK5 suggests close location of both N- and C-terminal membrane-
binding determinants implying that they can form a single interface and work synergistically to target GRK5 to the membrane. Binding of agonist to inactive
GPCR (light green, from the crystal structure of 2AR in complex with the inverse agonist ICI 118551, PDB code 3NY8) promotes GPCR activation. Docking of
GRK5 on an activated GPCR (green, from the 2ARGs complex structure, PDB code 3SN6) promotes full closure of the kinase domain and proper alignment of
phosphoacceptor siteson the receptor (greendashed line). CaMandGRK5autophosphorylation regulate the stabilityofGRK5association to themembraneand
GPCR. CaM (shown as a brownmodel) drives GRK5 redistribution frommembrane compartment to cytoplasm or nucleus, where GRK5 targets a different set of
substrates. GRK5 autophosphorylation sites (Ser484 and Thr485) are located at the presumed GRK5/lipid bilayer interface in the crystal structure, and hence,
autophosphorylation might change the electrostatic potential of GRK5 and destabilize GRK5 anchoring on the membrane.
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(74). Although bothCaM-binding regions onGRK5 have a pro-
pensity to form amphipathic -helices as predicted by second-
ary structure simulation (data not shown), the N-terminal
CaM-targeting region (residues 20–39) is largely unstructured
(Fig. 1D). Moreover, it is also involved in extensive intramolec-
ular contacts with RH domain residues. This includes Trp30, a
residue predicted to form an interface with CaM (72) that is
buried within a hydrophobic pocket of GRK5 and is thus inac-
cessible to CaM. Thus, it is reasonable to speculate that binding
of CaM to the N-terminal CaM-targeting region would involve
a structural rearrangement within the N-terminal CaM-bind-
ing region that would include dissociation from the RH domain
and subsequent helical formation induced by CaM binding.
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